$1.6bn Bharat Serums Buy Gives Mankind Dominance In Women's Health, R&D Engine

PE Firm Advent Exits At 22-23x FY25 EBITDA

With an eye-catching $1.6bn deal, Mankind has acquired Bharat Serums and Vaccines to add a high-barrier, specialty business, a credible biologics R&D engine and a complementary portfolio of women’s fertility and health treatments while PE firm Advent finds a profitable exit. What’s next?

Building Growth Through Acquisitions
Acquisitions Have Been Part Of Mankind's Growth Strategy • Source: Shutterstock

Mankind Pharma Ltd. Pharma, which went public via an initial public offering (IPO) just last year, has furthered its growth ambition with an acquisition of Bharat Serums And Vaccines Limited (BSV) at an enterprise value of INR136.3bn ($1.6bn) from private equity firm Advent International.

The enterprise value as of now translates to 22-23 times BSV's expected FY25 EBITDA (earnings before interest, tax and depreciation),...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip